Expression And Clinical Significance Of ER,PR,WT-1,Ki-67,CA125 In Ovarian Serous Cancer

Objectives: To analyze the expression of ER,PR,WT-1,Ki-67,CA125 in Ovarian Serous Cancer and the effect of neoadjuvant chemotherapy on the expression of tumor surface proteins,and to know whether its play a positive role in the prognosis of patients with ovarian cancer.Through researching the relationship between ER,PR,WT-1,Ki-67,CA125 and age,menopause,tumor type,pathological stage,ect,which would be a reference of clinical diagnosis,prognosis and hormone therapy.Methods: Eighty-two patients are selected from Jan 2014 to Dec 2015 of the first Bethune Hospital of Jilin University Obstetrics and Gynecology Department,including the pathological parameters:age,clinical stage,clinical differentiation,histological type,ect.The result of ER,PR,WT-1,Ki-67,CA125 are from the pathology department of our hospital.SPSS 21 statistical software was used to process the data,and useχ2test,Fisher exact probability analysis and Spearman to test the rate,the test level p> 0.05 is not statistically significant,p<0.05 is statistically significant,p<0.01 is much statistically significant.Results:1.The expression of ER,PR,WT-1,CA125 and Ki-67 in ovarian serous carcinoma are 76.83%、47.56%、85.37%、90.24%和 90.24%respectively.2.ER isintimately linked with FIGO staging and the existence of ascites(p< 0.05),and in phase Ⅲ and Ⅳ expression in ovarian serous carcinoma significantly higher than that of phase I,II,ascites group is higher than without ascites.3.PR is intimately linked with menopausal status(p< 0.05),its expression in postmenopausal group is higher.4.Except for with clinical stage(p<0.05),the expression of WT-1 is not correlated with other clinical pathological parameters,in phase Ⅲ and Ⅳ expression in ovarian serous carcinoma significantly higher than that of phase I,II5.The expression of Ki-67 is related to histology differentiation and clinical stage(p<0.05),of which the high level group is significantly higher than low level,phase Ⅲ and Ⅳ is higher than in phase I and II.6.The expression of CA125 is correlated with FIGO clinical stage,the existence of ascites and residual disease(p<0.05),of whichphase Ⅲ and Ⅳ is higher than in phase I and II.Ⅲ,ascites group is higher than without ascites,lesions residue that is equal or greater than 1 cm is higer.7.Among ER,PR,WT-1,Ki-67,CA125,there are correlation between ER and PR,ER and WT-1,WT-1 and CA125,Ki-67 and CA125(p< 0.05),and all are positive correlation,the others has no correlation.Conclusions:1,ER,PR,WT-1,Ki-67 and CA125 were expressed in ovarian serous carcinoma,its expression rate is respectively:76.83%、47.56%、85.37%、90.24% and 90.24%,which provide theoretical basis for the targeted therapy and endocrine therapy.2.WT-1 in patients with advanced ovarian serous carcinoma shows more positive expression,and is closely related to the clinical stage,which may be because WT-1 plays an active role in the tumor cells,and provide the basis for the targeted gene therapy.3.Ki-67 in ovarian serousis closely related to tissue differentiation,FIGO staging,CA125 has significant difference in the group of FIGO staging,presence of ascites and residual lesion group,this article is not check related lines of survival,but according to the pathology parameters and lifetime relationship,both in high expression may be associated with poor outcome.4.The expression of ER has significant differences between FIGO staging and ascites,PRis closely related to postmenopausal group,there is a positive correlation between ER and PR,both may work together in ovarian serous carcinoma,which provide reference for subsequent endocrine therapy.5.There is a positive correlation between the expression of ER and WT – 1,which may jointly involved in the development of ovarian cancer,but the mechanism need further research.6.There is a positive correlation between CA125 and WT-1,CA125 and Ki-67,so CA125,WT-1 and Ki-67 combined can improve the accuracy of detectionin the process of the decision of ovarian cancer.